Development and Implementation of Papillomavirus Prophylactic Vaccines

  title={Development and Implementation of Papillomavirus Prophylactic Vaccines},
  author={Ian H. Frazer},
  journal={The Journal of Immunology},
  pages={4007 - 4011}
  • I. Frazer
  • Published 1 May 2014
  • Medicine
  • The Journal of Immunology
Translation of basic scientific findings into practical patient outcomes is a significant exercise even when the goal is conceptually straightforward, as in the development of a vaccine for an infectious disease. Recognition of the association of cervical cancer with papillomavirus infection encouraged development of a vaccine to help with prevention of this very common cancer, causing over 250,000 deaths each year worldwide. To introduce a vaccine program, it was however necessary to develop a… 

Figures from this paper

Reports on COVID-19 Vaccines and Vaccination in Nigeria
Understudying the various brands of vaccines approved by the World Health Organization for covid, their mechanism of actions and the outcomes of these vaccines (benefits and adverse effects) found to be able to offer immunity against them.
Antiviral therapy for the sexually transmitted viruses: recent updates on vaccine development
The efforts directed toward development of effective vaccines using different laboratory animal models including mice, guinea pig or non-human primates in preclinical trials, and human in clinical trials with different phases are discussed.
Construction and evaluation of human papillomavirus genotype 18 pseudovirions
The cotransfection of HPV18 L1/L2 coding plasmid as well as pEGP-N1 reporter plasmids into the HEK 293FT cell led to the assembly of the pseudovirion harboring the reporter gene.
Exploring the Papillomaviral Proteome to Identify Potential Candidates for a Chimeric Vaccine against Cervix Papilloma Using Immunomics and Computational Structural Vaccinology
SGD58 is a stable protein that is soluble, antigenic, and non-allergenic and may prompt the creation of a vaccine against cervix papilloma, which is considered to be the second most predominant genotype in cervical cancer incidents in China.
The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon
The nonavalent HPV vaccine appears to be safe and effective in preventing persistent infection and precancerous lesions associated with HPV types 16/18/31/33/45/52/58, as well as genital warts related to HPV types 6 and 11.
HPV Vaccine: Updates and Highlights
This non-systematic review aims to summarize the HPV epidemiology and the vaccine development to review the landmark trials of HPV vaccine, to present to most remarkable results from clinical trials and the real world, and to stress the challenges and the barriers for HPV vaccine implementation.
Rodent Papillomaviruses
This review has summarized the knowledge gained about PV biology from the study of rodent papillomaviruses and point out the remaining gaps that can provide new research opportunities.
Impact of HPV vaccination on anogenital warts and respiratory papillomatosis
Longer-term monitoring will reveal whether this impact continues under 9vHPV programs, and whether current declines in AGW are mirrored by declines in RRP.
Therapeutic DNA Vaccine Against HPV16-Associated Cancer.
A detailed protocol of intradermal delivery of a therapeutic DNA vaccine and a grafting model of neoantigen expressing skin is described to evaluate vaccine efficacy against HPV16 mediated hyperproliferative epithelium in mice.


Prophylactic human papillomavirus vaccines.
This Review examines prophylactic HPV subunit vaccines based on the ability of the viral L1 capsid protein to form virus-like particles that induce high levels of neutralizing antibodies that confer complete type-specific protection against persistent infection and associated lesions in fully vaccinated women.
Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics
A recent vaccine approved by the Food and Drug Administration is the recombinant quadrivalent human papillomavirus (HPV) vaccine (Merck, Gardasil®).
Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.
  • J. Suzich, S. Ghim, R. Schlegel
  • Biology, Medicine
    Proceedings of the National Academy of Sciences of the United States of America
  • 1995
The results indicate the feasibility of developing a human vaccine to prevent mucosal papillomas, which can progress to malignancy, and suggest adjuvants appeared useful for prolonging the host immune response.
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.
The HPV16 L1 VLP vaccine is well tolerated and is highly immunogenic even without adjuvant, with the majority of the recipients achieving serum antibody titers that were approximately 40-fold higher than what is observed in natural infection.
New Approaches to Immunotherapy for HPV Associated Cancers
Possible new approaches to immunotherapy for HPV associated cancer are discussed, based on recent advances in knowledge of the immunobiology of HPV infection, of epithelial immunology and of immunoregulation, with a brief overview on previous and current HPV vaccine clinical trials.
Female human papillomavirus (HPV) vaccination: global uptake and the impact of attitudes.
Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses
Establishment of an International Standard for antibodies to HPV 16 would facilitate the comparison of HPV antibody measurements between laboratories and assays, and assist with HPV vaccine development and epidemiology.
Clinical update of the AS04-Adjuvanted human Papillomavirus-16/18 cervical cancer vaccine, cervarix®
  • T. Schwarz
  • Biology, Medicine
    Advances in therapy
  • 2009
Final results of a large phase 3 trial recently showed Cervarix substantially reduced the overall burden of cervical precancerous lesions by 70.2% in an HPV-naïve population approximating young girls prior to sexual debut, the target of most current vaccination programs.
Studies on vaccination against papillomaviruses: a comparison of purified virus, tumour extract and transformed cells in prophylactic vaccination
Calves were vaccinated with two preparations made from one cutaneous fibropapilloma induced by bovine papillomavirus type 2 (BPV-2). One vaccine consisted of homogenised tumour; the other contained